Margetuximab
- Generic Name
- Margetuximab
- Brand Names
- Margenza
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1350624-75-7
- Unique Ingredient Identifier
- K911R84KEW
- Background
The HER2 oncoprotein, the product of the human ERBB2/mouse neu genes, is a member of the HER family of receptor tyrosine kinases that includes the epidermal growth factor receptor (EGFR). Of the various subtypes of breast cancer, HER2-positive breast cancer is characterized by ERBB2 overexpression, a higher grade, a more aggressive phenotype, and a worse pro...
- Indication
Margetuximab is an anti-HER2 monoclonal antibody indicated, in combination with chemotherapy, for the treatment of metastatic HER2-positive breast cancer in adult patients who have received two or more prior anti-HER2 regimens with at least one prior regimen for metastatic disease.
- Associated Conditions
- Metastatic Breast Cancer With HER2 Positive
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.